Day: October 24, 2025

TORONTO, Oct. 24, 2025 (GLOBE NEWSWIRE) — Middlefield Global Dividend Growers ETF (TSX: MDIV) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2025 will be payable to unitholders of Middlefield Global Dividend Growers ETF as follows:Record Date Payable Date Distribution Per Trust UnitOctober 31, 2025 November 14, 2025 $0.06November 30, 2025 December 15, 2025 $0.06December 31, 2025 January 15, 2026 $0.06The trust units trade on the Toronto Stock Exchange under the symbol MDIV. The Fund offers a distribution reinvestment plan (“DRIP”) for unitholders which provides unitholders with the ability to automatically reinvest distributions, commission free, and realize the benefits of compound growth. Unitholders can enroll in the DRIP program by contacting their investment advisor. Middlefield...

Institutional Interest Surging DENVER, Oct. 24, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Wall Street and Madison Avenue are finally catching up to what early investors already knew: VENU (NYSE American: VENU) isn’t just another real estate play it’s building the infrastructure for America’s next entertainment revolution. VENU will offer fractional ownership opportunities to some of the most modern, sophisticated amphitheaters in the country! VENU has launched a nationwide advertising campaign airing across five major U.S. media networks; FOX News, FOX Business, CNBC, Peacock, and Newsmax, reaching millions of viewers through both broadcast and streaming platforms. The campaign started October 15th and...

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P

3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignancies Disease stabilization observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition (FBXW7, CCNE1, KRAS G12V and TP53) Dose escalation continues, with patients now enrolling in 150 mg cohort Preliminary results from ACESOT-1051 trial through September 17, 2025 to be featured in poster presentation today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsDOYLESTOWN, Pa., Oct. 24, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while...

Rebel Engine achieves 72× surge in daily Steam wishlists, signaling accelerating demand and strong pre-launch traction CULVER CITY, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) —  Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, shared highlights from a series of successful game showcases and updates across its growing publishing portfolio, underscoring continued engagement and visibility. Snail Games’ upcoming hybrid action title, Rebel Engine, demonstrated significant momentum during Steam Next Fest, with daily wishlist additions increasing more than 72 times compared to the pre-festival period. This surge contributed to a 46% overall increase in total wishlists, underscoring the game’s accelerating traction ahead of its official...

FUKUOKA, Japan, Oct. 24, 2025 (GLOBE NEWSWIRE) — rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, announced a strategic partnership with China Zhongqing International Holdings Co., Ltd. (“Zhongqing International”) to implement the Company’s Free Labor Union Program for Japan’s Technical Intern Training and Specified Skilled Worker Programs. Japan’s Technical Intern Training and Specified Skilled Worker programs were originally designed to bring foreign workers into Japan, allowing them to develop technical skills while addressing the country’s labor needs in essential industries. However, in practice, certain participating companies in the program have been criticized for imposing long working hours, unfair oversight, and human-rights violations. Over the...

Geneva, Switzerland, Oct. 24, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that its ordinary shares have been approved for trading on the NASDAQ Global Select Market, effective October 27, 2025. The uplisting from the NASDAQ Capital Market reflects SEALSQ’s continued development, operational progress, and adherence to the highest financial and governance standards required by NASDAQ. The NASDAQ Global Select Market is the highest tier of the NASDAQ Stock Market, reserved for companies that meet the most stringent financial and liquidity standards. SEALSQ’s inclusion in this tier aligns with its vision to expand its presence among...

HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria. FibroBiologics will deliver a company presentation at 4:15 p.m. CET on Tuesday, November 4, and will be available for one-on-one investor meetings throughout the event. For more information, please visit FibroBiologics’ website or email FibroBiologics at: info@fibrobiologics.com. About FibroBiologics Based...

LOWELL, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI) plans to announce financial results for its fourth quarter and fiscal year 2025 ended October 3, 2025, before market open on Thursday, November 6, 2025. In conjunction with the release, MACOM will conduct a conference call at 8:30 a.m. Eastern Time on Thursday, November 6, 2025, hosted by Mr. Stephen G. Daly, President and Chief Executive Officer, and Mr. John F. Kober, Senior Vice President and Chief Financial Officer. Please visit MACOM’s Investor Relations Website to register for a user-specific access code for the live call or to access the live webcast. A replay of the call will be available within 24 hours and remain accessible by all interested parties for approximately 90 days. About MACOMMACOM designs and...